Saxagliptin vs Teneligliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Saxagliptin · Onglyza

Rights held by AstraZeneca and partners; US product discontinued

Approved in Type 2 Diabetessmall molecule
Reliable signal

NCT00121667 · Phase 3 · completed

Large randomized, double-blind, placebo-controlled phase 3 trial (743 treated participants across three saxagliptin doses and one placebo arm, all on background metformin). The primary endpoint was change from baseline in hemoglobin A1c at Week 24, an accepted hard glycemic measure for type 2 diabetes, and every saxagliptin dose showed a statistically significant improvement versus placebo (adjusted differences of -0.73, -0.83, and -0.72 percentage points, each p<0.0001). Because the trial was adequately powered, double-blind, and placebo-controlled, and the primary comparison was met, this is strong evidence for saxagliptin's efficacy.

Next expected readout: February 2027 · NCT02969798 (registry estimate)

Reported efficacy

Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07) (met)

Result source: NCT00121667

Teneligliptin · Tenelia

Marketed by Tanabe Pharma Corporation and partners

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT00974090 · Phase 3 · completed

This randomized, double-blind, placebo-controlled Phase 3 trial added teneligliptin 20 mg or placebo to glimepiride in 194 Japanese adults with type 2 diabetes. The primary endpoint was the change in HbA1c at week 12. Teneligliptin lowered HbA1c by 1.0 percentage point more than placebo (p<0.001), so the primary endpoint was met. A 40-week open-label teneligliptin period followed. Source: the peer-reviewed trial report (Kadowaki and Kondo 2014) and CT.gov posted results.

Reported efficacy

HbA1c (Change from Visit 1(Baseline Visit) in HbA1c at Visit 5(week 16)): Change in HbA1c from baseline to week 16, teneligliptin (MP-513) vs placebo (both plus metformin): between-group difference -0.78 percentage points; fasting plasma glucose difference -1.24 mmol/L (22.42 mg/dL). (met)

Result source: NCT01805830

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSaxagliptinTeneligliptin
HbA1c, change-0.7% vs -0.3%−0.4 vs placebo5 mg · wk 24 · n 300NCT00757588
19 other results
  • 7.1% vs 7.5% 5 mg · wk 24 · n 275 · Phase 3 · primary NCT00661362
  • -0.5% vs -0.2% 5 mg · wk 24 · n 139 · Phase 3 · primary NCT01619059
  • -0.8% vs -0.1% wk 24 · n 158 · Phase 3 · primary NCT01646320
  • -0.7% vs -0.1% wk 24 · n 127 · Phase 3 · primary NCT01128153
  • 0.1% vs 0.5% wk 26 · n 82 · Phase 3 · primary NCT03199053
  • -0.7% vs 0.6% wk 16 · n 4 · Phase 3 · primary NCT01204775
  • -1% vs 0.9% wk 16 · n 4 · Phase 3 · primary NCT01434186
  • -1.4% vs -1.0% dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 218 · Phase 3 · primary NCT02419612
  • -1.7% vs -1.5% wk 24 · n 319 · Phase 3 · primary NCT02551874
  • -1.0% vs -0.7% wk 24 · n 290 · Phase 3 · primary NCT02681094
  • -1.4% vs -1.1% wk 26 · n 224 · Phase 3 · primary NCT02284893
  • -0.2% vs -0.7% 5 mg · wk 26 · n 25 · Phase 3 · secondary NCT03199053
  • 0.1% vs -0.7% 2.5 mg · wk 26 · n 24 · Phase 3 · secondary NCT03199053
  • -0.8% vs -1.0% 10mg · wk 52 · n 311 · Phase 4 · primary NCT02471404
  • -1.2% vs -1.0% 5mg and 10mg · wk 52 · n 312 · Phase 4 · primary NCT02471404
  • -0.8% vs -0.8% wk 24 · n 238 · Phase 4 · primary NCT02243176
  • -0.8% vs -0.8% wk 24 · n 219 · Phase 4 · primary NCT02243176
  • -0.5% vs -0.4% wk 24 · n 146 · Phase 4 · primary NCT01006590
  • -0.4% vs -0.6% 5 mg · wk 52 · n 353 · Phase 4 · secondary NCT01006603
-0.7% vs -0.0%−0.7 vs placebo20 mg · wk 24 · n 122NCT02924064
12 other results
  • -0.9% vs -0.1% 20 mg · wk 24 · n 125 · Phase 3 · primary NCT02916706
  • -0.6% vs 0.2% 20 mg · wk 12 · n 99 · Phase 3 · primary NCT00998881
  • -0.9% vs 0% wk 24 · n 77 · Phase 3 · primary NCT02354222
  • -0.7% vs 0.3% wk 12 · n 96 · Phase 3 · primary NCT00974090
  • -0.8% vs 0.1% 20 mg · wk 12 · n 79 · Phase 2 · primary NCT00628212
  • -0.8% vs 0.1% 10 mg · wk 12 · n 84 · Phase 2 · primary NCT00628212
  • -0.9% vs -0.3% 40 mg · wk 24 · n 88 · Phase 2 · primary NCT00971243
  • -0.9% vs 0.1% 40 mg · wk 12 · n 81 · Phase 2 · primary NCT00628212
  • -0.8% vs -0.3% 20 mg · wk 24 · n 91 · Phase 2 · primary NCT00971243
  • -0.7% vs -0.3% 10 mg · wk 24 · n 93 · Phase 2 · primary NCT00971243
  • -0.6% vs -0.3% 5 mg · wk 24 · n 87 · Phase 2 · primary NCT00971243
  • -0.9% vs -0.1% wk 16 · n 77 · Phase 4 · primary NCT02081599
Body weight, change (kg)-1.9 vs -0.4−1.5 vs placebowk 24 · n 158NCT01646320
7 other results
  • -3.1 vs 0.9 dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 224 · Phase 3 · secondary NCT02419612
  • -1.9 vs -0.5 wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • -1.5 vs 2.1 wk 24 · n 319 · Phase 3 · secondary NCT02551874
  • -2.0 vs -0.4 wk 24 · n 290 · Phase 3 · secondary NCT02681094
  • -3.5 vs 1.8 10mg · wk 52 · n 311 · Phase 4 · secondary NCT02471404
  • -3.1 vs 1.8 5mg and 10mg · wk 52 · n 312 · Phase 4 · secondary NCT02471404
  • -1.4 vs -2.0 wk 24 · n 238 · Phase 4 · secondary NCT02243176
—Not posted · NCT01798238
HbA1c below 7%44.4% vs 16.6%+27.8 vs placebo10 mg · wk 24 · n 180NCT00121667
15 other results
  • 41.1% vs 23.9% 10 mg · wk 24 · n 95 · Phase 3 · secondary NCT00121641
  • 43.5% vs 16.6% 5 mg · wk 24 · n 186 · Phase 3 · secondary NCT00121667
  • 37.9% vs 23.9% 5 mg · wk 24 · n 103 · Phase 3 · secondary NCT00121641
  • 22.1% vs 13.3% 5 mg · wk 24 · n 104 · Phase 3 · secondary NCT00918879
  • 45.8% vs 28.8% 5 mg · wk 24 · n 277 · Phase 3 · secondary NCT00698932
  • 37.1% vs 16.6% 2.5 mg · wk 24 · n 186 · Phase 3 · secondary NCT00121667
  • 35% vs 23.9% 2.5 mg · wk 24 · n 100 · Phase 3 · secondary NCT00121641
  • 37.5% vs 24.2% 2.5 mg · wk 12 · n 73 · Phase 3 · secondary NCT00885378
  • 21.3% vs 10% wk 26 · n 61 · Phase 3 · secondary NCT03199053
  • 36.7% vs 13.3% wk 24 · n 158 · Phase 3 · secondary NCT01646320
  • 21.4% vs 11.7% dapagliflozin 10 mg, saxagliptin 5 mg · wk 156 · n 227 · Phase 3 · secondary NCT02419612
  • 44.3% vs 34.3% dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 227 · Phase 3 · secondary NCT02419612
  • 37.3% vs 25.1% wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • 37.2% vs 26.1% wk 18 · n 137 · Phase 3 · secondary NCT00960076
  • 38.3% vs 41.5% wk 24 · n 230 · Phase 4 · secondary NCT02243176
—Not posted · NCT01798238
Fasting plasma glucose, change-0.6 vs -0.3−0.2 vs placebo5 mg · wk 24 · n 300NCT00757588
11 other results
  • -0.5 vs -0.3 5 mg · wk 24 · n 139 · Phase 3 · secondary NCT01619059
  • -1.8 vs -0.3 wk 24 · n 158 · Phase 3 · secondary NCT01646320
  • -0.3 vs 0.1 wk 24 · n 121 · Phase 3 · secondary NCT01128153
  • 0.1 vs 0.2 wk 26 · n 80 · Phase 3 · secondary NCT03199053
  • -1.8 vs -0.6 wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • -2.4 vs -1.0 5 mg · wk 26 · n 25 · Phase 3 · secondary NCT03199053
  • -0.6 vs -1.0 2.5 mg · wk 26 · n 23 · Phase 3 · secondary NCT03199053
  • -1.6 vs -1.5 10mg · wk 52 · n 311 · Phase 4 · secondary NCT02471404
  • -0.7 vs -1.3 5 mg · wk 52 · n 344 · Phase 4 · secondary NCT01006603
  • -2.1 vs -1.5 5mg and 10mg · wk 52 · n 312 · Phase 4 · secondary NCT02471404
  • -1.0 vs -1.0 wk 24 · n 238 · Phase 4 · secondary NCT02243176
-0.8 vs 0.2−0.9 vs placebo20 mg · wk 24 · n 122NCT02924064
13 other results
  • -1.2 vs -0.1 20 mg · wk 24 · n 125 · Phase 3 · secondary NCT02916706
  • -1.1 vs -0.0 20 mg · wk 12 · n 99 · Phase 3 · secondary NCT00998881
  • -1.1 vs -0.4 20 mg · wk 4 · n 33 · Phase 3 · secondary NCT01072331
  • -1.1 vs -0.4 10 mg · wk 4 · n 34 · Phase 3 · secondary NCT01072331
  • -0.3 vs 0.6 wk 24 · n 77 · Phase 3 · secondary NCT02354222
  • -0.8 vs 0.2 20 mg · wk 12 · n 79 · Phase 2 · secondary NCT00628212
  • -0.8 vs 0.2 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT00628212
  • -1.2 vs -0.2 40 mg · wk 24 · n 88 · Phase 2 · secondary NCT00971243
  • -0.9 vs 0.2 40 mg · wk 12 · n 81 · Phase 2 · secondary NCT00628212
  • -1.0 vs -0.2 20 mg · wk 24 · n 91 · Phase 2 · secondary NCT00971243
  • -0.8 vs -0.2 10 mg · wk 24 · n 93 · Phase 2 · secondary NCT00971243
  • -0.9 vs -0.2 5 mg · wk 24 · n 87 · Phase 2 · secondary NCT00971243
  • -0.3 vs 0.4 wk 16 · n 77 · Phase 4 · secondary NCT02081599
3-point MACE (% with event)7.4% vs 7.4%±0 vs placebon 8280NCT01107886—Not posted · NCT01798238

HbA1c, change

Saxagliptin
-0.7% vs -0.3%−0.4 vs placebo5 mg · wk 24 · n 300NCT00757588
19 other results
  • 7.1% vs 7.5% 5 mg · wk 24 · n 275 · Phase 3 · primary NCT00661362
  • -0.5% vs -0.2% 5 mg · wk 24 · n 139 · Phase 3 · primary NCT01619059
  • -0.8% vs -0.1% wk 24 · n 158 · Phase 3 · primary NCT01646320
  • -0.7% vs -0.1% wk 24 · n 127 · Phase 3 · primary NCT01128153
  • 0.1% vs 0.5% wk 26 · n 82 · Phase 3 · primary NCT03199053
  • -0.7% vs 0.6% wk 16 · n 4 · Phase 3 · primary NCT01204775
  • -1% vs 0.9% wk 16 · n 4 · Phase 3 · primary NCT01434186
  • -1.4% vs -1.0% dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 218 · Phase 3 · primary NCT02419612
  • -1.7% vs -1.5% wk 24 · n 319 · Phase 3 · primary NCT02551874
  • -1.0% vs -0.7% wk 24 · n 290 · Phase 3 · primary NCT02681094
  • -1.4% vs -1.1% wk 26 · n 224 · Phase 3 · primary NCT02284893
  • -0.2% vs -0.7% 5 mg · wk 26 · n 25 · Phase 3 · secondary NCT03199053
  • 0.1% vs -0.7% 2.5 mg · wk 26 · n 24 · Phase 3 · secondary NCT03199053
  • -0.8% vs -1.0% 10mg · wk 52 · n 311 · Phase 4 · primary NCT02471404
  • -1.2% vs -1.0% 5mg and 10mg · wk 52 · n 312 · Phase 4 · primary NCT02471404
  • -0.8% vs -0.8% wk 24 · n 238 · Phase 4 · primary NCT02243176
  • -0.8% vs -0.8% wk 24 · n 219 · Phase 4 · primary NCT02243176
  • -0.5% vs -0.4% wk 24 · n 146 · Phase 4 · primary NCT01006590
  • -0.4% vs -0.6% 5 mg · wk 52 · n 353 · Phase 4 · secondary NCT01006603
Teneligliptin
-0.7% vs -0.0%−0.7 vs placebo20 mg · wk 24 · n 122NCT02924064
12 other results
  • -0.9% vs -0.1% 20 mg · wk 24 · n 125 · Phase 3 · primary NCT02916706
  • -0.6% vs 0.2% 20 mg · wk 12 · n 99 · Phase 3 · primary NCT00998881
  • -0.9% vs 0% wk 24 · n 77 · Phase 3 · primary NCT02354222
  • -0.7% vs 0.3% wk 12 · n 96 · Phase 3 · primary NCT00974090
  • -0.8% vs 0.1% 20 mg · wk 12 · n 79 · Phase 2 · primary NCT00628212
  • -0.8% vs 0.1% 10 mg · wk 12 · n 84 · Phase 2 · primary NCT00628212
  • -0.9% vs -0.3% 40 mg · wk 24 · n 88 · Phase 2 · primary NCT00971243
  • -0.9% vs 0.1% 40 mg · wk 12 · n 81 · Phase 2 · primary NCT00628212
  • -0.8% vs -0.3% 20 mg · wk 24 · n 91 · Phase 2 · primary NCT00971243
  • -0.7% vs -0.3% 10 mg · wk 24 · n 93 · Phase 2 · primary NCT00971243
  • -0.6% vs -0.3% 5 mg · wk 24 · n 87 · Phase 2 · primary NCT00971243
  • -0.9% vs -0.1% wk 16 · n 77 · Phase 4 · primary NCT02081599

Body weight, change (kg)

Saxagliptin
-1.9 vs -0.4−1.5 vs placebowk 24 · n 158NCT01646320
7 other results
  • -3.1 vs 0.9 dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 224 · Phase 3 · secondary NCT02419612
  • -1.9 vs -0.5 wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • -1.5 vs 2.1 wk 24 · n 319 · Phase 3 · secondary NCT02551874
  • -2.0 vs -0.4 wk 24 · n 290 · Phase 3 · secondary NCT02681094
  • -3.5 vs 1.8 10mg · wk 52 · n 311 · Phase 4 · secondary NCT02471404
  • -3.1 vs 1.8 5mg and 10mg · wk 52 · n 312 · Phase 4 · secondary NCT02471404
  • -1.4 vs -2.0 wk 24 · n 238 · Phase 4 · secondary NCT02243176
Teneligliptin
—Not posted · NCT01798238

HbA1c below 7%

Saxagliptin
44.4% vs 16.6%+27.8 vs placebo10 mg · wk 24 · n 180NCT00121667
15 other results
  • 41.1% vs 23.9% 10 mg · wk 24 · n 95 · Phase 3 · secondary NCT00121641
  • 43.5% vs 16.6% 5 mg · wk 24 · n 186 · Phase 3 · secondary NCT00121667
  • 37.9% vs 23.9% 5 mg · wk 24 · n 103 · Phase 3 · secondary NCT00121641
  • 22.1% vs 13.3% 5 mg · wk 24 · n 104 · Phase 3 · secondary NCT00918879
  • 45.8% vs 28.8% 5 mg · wk 24 · n 277 · Phase 3 · secondary NCT00698932
  • 37.1% vs 16.6% 2.5 mg · wk 24 · n 186 · Phase 3 · secondary NCT00121667
  • 35% vs 23.9% 2.5 mg · wk 24 · n 100 · Phase 3 · secondary NCT00121641
  • 37.5% vs 24.2% 2.5 mg · wk 12 · n 73 · Phase 3 · secondary NCT00885378
  • 21.3% vs 10% wk 26 · n 61 · Phase 3 · secondary NCT03199053
  • 36.7% vs 13.3% wk 24 · n 158 · Phase 3 · secondary NCT01646320
  • 21.4% vs 11.7% dapagliflozin 10 mg, saxagliptin 5 mg · wk 156 · n 227 · Phase 3 · secondary NCT02419612
  • 44.3% vs 34.3% dapagliflozin 10 mg, saxagliptin 5 mg · wk 52 · n 227 · Phase 3 · secondary NCT02419612
  • 37.3% vs 25.1% wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • 37.2% vs 26.1% wk 18 · n 137 · Phase 3 · secondary NCT00960076
  • 38.3% vs 41.5% wk 24 · n 230 · Phase 4 · secondary NCT02243176
Teneligliptin
—Not posted · NCT01798238

Fasting plasma glucose, change

Saxagliptin
-0.6 vs -0.3−0.2 vs placebo5 mg · wk 24 · n 300NCT00757588
11 other results
  • -0.5 vs -0.3 5 mg · wk 24 · n 139 · Phase 3 · secondary NCT01619059
  • -1.8 vs -0.3 wk 24 · n 158 · Phase 3 · secondary NCT01646320
  • -0.3 vs 0.1 wk 24 · n 121 · Phase 3 · secondary NCT01128153
  • 0.1 vs 0.2 wk 26 · n 80 · Phase 3 · secondary NCT03199053
  • -1.8 vs -0.6 wk 26 · n 224 · Phase 3 · secondary NCT02284893
  • -2.4 vs -1.0 5 mg · wk 26 · n 25 · Phase 3 · secondary NCT03199053
  • -0.6 vs -1.0 2.5 mg · wk 26 · n 23 · Phase 3 · secondary NCT03199053
  • -1.6 vs -1.5 10mg · wk 52 · n 311 · Phase 4 · secondary NCT02471404
  • -0.7 vs -1.3 5 mg · wk 52 · n 344 · Phase 4 · secondary NCT01006603
  • -2.1 vs -1.5 5mg and 10mg · wk 52 · n 312 · Phase 4 · secondary NCT02471404
  • -1.0 vs -1.0 wk 24 · n 238 · Phase 4 · secondary NCT02243176
Teneligliptin
-0.8 vs 0.2−0.9 vs placebo20 mg · wk 24 · n 122NCT02924064
13 other results
  • -1.2 vs -0.1 20 mg · wk 24 · n 125 · Phase 3 · secondary NCT02916706
  • -1.1 vs -0.0 20 mg · wk 12 · n 99 · Phase 3 · secondary NCT00998881
  • -1.1 vs -0.4 20 mg · wk 4 · n 33 · Phase 3 · secondary NCT01072331
  • -1.1 vs -0.4 10 mg · wk 4 · n 34 · Phase 3 · secondary NCT01072331
  • -0.3 vs 0.6 wk 24 · n 77 · Phase 3 · secondary NCT02354222
  • -0.8 vs 0.2 20 mg · wk 12 · n 79 · Phase 2 · secondary NCT00628212
  • -0.8 vs 0.2 10 mg · wk 12 · n 84 · Phase 2 · secondary NCT00628212
  • -1.2 vs -0.2 40 mg · wk 24 · n 88 · Phase 2 · secondary NCT00971243
  • -0.9 vs 0.2 40 mg · wk 12 · n 81 · Phase 2 · secondary NCT00628212
  • -1.0 vs -0.2 20 mg · wk 24 · n 91 · Phase 2 · secondary NCT00971243
  • -0.8 vs -0.2 10 mg · wk 24 · n 93 · Phase 2 · secondary NCT00971243
  • -0.9 vs -0.2 5 mg · wk 24 · n 87 · Phase 2 · secondary NCT00971243
  • -0.3 vs 0.4 wk 16 · n 77 · Phase 4 · secondary NCT02081599

3-point MACE (% with event)

Saxagliptin
7.4% vs 7.4%±0 vs placebon 8280NCT01107886
Teneligliptin
—Not posted · NCT01798238
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety

Coverage. Saxagliptin: 9 of 9 rows · Teneligliptin: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSaxagliptin
Rows use multiple source trials
Teneligliptin
Rows use multiple source trials
Fasting Plasma Glucose
absolute change · mmol/L
No placebo or comparator arm
-0.55 mmol/L @ 24wka,b,c
NCT01608724 · Phase 4 · registry result, not featured evidence
1 other source trial
-0.62 mmol/L @ 24wk*
NCT02104804 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -11.23 mg/dL as posted
-0.69 mmol/L @ 52wk*d,a,b,c
NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -12.4 mg/dL as posted
show 1 more dose
-0.94 mmol/L @ 52wk*
NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -17 mg/dL as posted
FPG
absolute change · mmol/L
-0.29 vs 0.15 placebo mmol/L @ 24wk*b,e,f
NCT01128153 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -5.28 mg/dL as posted
-0.96 vs 0.54 placebo mmol/L @ 12wk*b,e,f
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -17.3 mg/dL as posted
HbA1c
absolute change · percentage points
No placebo or comparator arm
-0.64% (n=229) @ 24wkb,e
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
-0.94% @ 24wkteneligliptin 20mgb,e
NCT01798238 · Phase 3 · sponsor-reported, not registry data
PPG 2H
absolute change · mmol/L
-0.77 vs -1.07 Acarbose mmol/L @ 24wka,b,e,f
NCT02243176 · Phase 4 · registry result, not featured evidence
2 other source trials
-0.65 vs 0.28 placebo mmol/L @ 24wk*
NCT01128153 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -11.66 mg/dL as posted
-0.65 vs 0.28 placebo mmol/L @ 24wk
NCT01128153 · Phase 3 · registry result, not featured evidence
-2.39 vs 0.33 placebo mmol/L @ 12wk*a,b,e,f
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -43.1 mg/dL as posted
PPG 2h Change mg/dL
absolute change · mmol/L
-4.08 vs -2.11 placebo mmol/L @ 24wk*b
NCT01646320 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -73.5 mg/dL as posted
2 other source trials
-2.06 vs -1.74 placebo mmol/L @ 24wk*5 mg
NCT01619059 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -37.1 mg/dL as posted
-1.51 vs -0.23 placebo mmol/L @ 24wk*5 mg
NCT00757588 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -27.2 mg/dL as posted
-1.96 vs 0.13 placebo mmol/L @ 24wk*b
NCT02354222 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -35.3 mg/dL as posted
Dropout rate
22.7%10 mgg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 43 more results
25.1%5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
22.9%2.5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
29.6%10 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
35.8%5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
28.4%2.5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%
NCT02024477 · Phase 4 · registry result, not featured evidence
10.5%10mg
NCT02471404 · Phase 4 · registry result, not featured evidence
4.5%5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
5.7%
NCT02243176 · Phase 4 · registry result, not featured evidence
17.1%
NCT01608724 · Phase 4 · registry result, not featured evidence
2.4%
NCT01107886 · Phase 4 · registry result, not featured evidence
19.7%5 mg
NCT01006603 · Phase 4 · registry result, not featured evidence
19%
NCT01006590 · Phase 4 · registry result, not featured evidence · add on
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
5.7%Saxagliptin
NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy
7.5%dapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
8.6%
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
12.6%
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
8.2%
NCT02284893 · Phase 3 · registry result, not featured evidence · combination
25%
NCT01204775 · Phase 3 · registry result, not featured evidence
0%
NCT01434186 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
6.8%Saxagliptin Plus Insulin
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
—DAPA + SAXA + MET
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
7.5%Dapa+Saxa+Met
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
7.2%5 mg
NCT01619059 · Phase 3 · registry result, not featured evidence · combination
—
NCT01606007 · Phase 3 · registry result, not featured evidence · combination
12.4%
NCT01128153 · Phase 3 · registry result, not featured evidence
5.8%
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
61.4%
NCT00575588 · Phase 3 · registry result, not featured evidence · combination
5.6%5 mg
NCT00918879 · Phase 3 · registry result, not featured evidence
4.3%5 mg + Metformin XR 1500 mg
NCT00918138 · Phase 3 · registry result, not featured evidence · combination
11.8%5 mg
NCT00757588 · Phase 3 · registry result, not featured evidence · combination
50.6%
NCT00614939 · Phase 3 · registry result, not featured evidence
10.8%2.5 mg
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
15%5 mg
NCT00374907 · Phase 3 · registry result, not featured evidence
7.7%5 mg
NCT00698932 · Phase 3 · registry result, not featured evidence
10.2%5 mg
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
1%Teneli / Teneli + SUh
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 28 more results
—Teneli/Teneli + SU (Data Through W
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
—Teneli/Teneli + SU (Data Through W
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
10.6%Teneligliptin
NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15.7%Teneligliptin + Sulfonylurea
NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.6%Teneli (Teneligliptin) /Teneli + I
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
—Teneli (Teneligliptin) /Teneli + I
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
—Teneli (Teneligliptin)/Teneli + In
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
19.5%20 mg
NCT02924064 · Phase 3 · registry result, not featured evidence · combination
11.8%20 mg
NCT02916706 · Phase 3 · registry result, not featured evidence
7.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
5.2%
NCT02354222 · Phase 3 · registry result, not featured evidence · combination
7.1%Teneligliptin
NCT01301833 · Phase 3 · registry result, not featured evidence
9.3%Teneligliptin and Alpha-glucosidas
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
7.4%Teneligliptin and Biguanide
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
10%Teneligliptin and Glinide
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
0%20 mg
NCT01072331 · Phase 3 · registry result, not featured evidence
0%10 mg
NCT01072331 · Phase 3 · registry result, not featured evidence
2%20 mg
NCT00998881 · Phase 3 · registry result, not featured evidence
—40 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
15.9%40 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—20 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
20.9%20 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—10 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
11.8%10 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
21.8%5 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
3.8%20 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
1.2%10 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
6.2%40 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
2.8%10 mgg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 43 more results
3.1%5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.6%2.5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.1%10 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.8%5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.9%2.5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
—
NCT02024477 · Phase 4 · registry result, not featured evidence
2.2%10mg
NCT02471404 · Phase 4 · registry result, not featured evidence
0.3%5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
0.8%
NCT02243176 · Phase 4 · registry result, not featured evidence
2%
NCT01608724 · Phase 4 · registry result, not featured evidence
—
NCT01107886 · Phase 4 · registry result, not featured evidence
4.2%5 mg
NCT01006603 · Phase 4 · registry result, not featured evidence
1.4%
NCT01006590 · Phase 4 · registry result, not featured evidence · add on
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—Saxagliptin
NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy
0.4%dapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
—
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
3.4%
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
0.4%
NCT02284893 · Phase 3 · registry result, not featured evidence · combination
—
NCT01204775 · Phase 3 · registry result, not featured evidence
—
NCT01434186 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
1.7%Saxagliptin Plus Insulin
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
—DAPA + SAXA + MET
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
1.9%Dapa+Saxa+Met
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
0%5 mg
NCT01619059 · Phase 3 · registry result, not featured evidence · combination
—
NCT01606007 · Phase 3 · registry result, not featured evidence · combination
0.8%
NCT01128153 · Phase 3 · registry result, not featured evidence
0.7%
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
2.6%
NCT00575588 · Phase 3 · registry result, not featured evidence · combination
—5 mg
NCT00918879 · Phase 3 · registry result, not featured evidence
—5 mg + Metformin XR 1500 mg
NCT00918138 · Phase 3 · registry result, not featured evidence · combination
2%5 mg
NCT00757588 · Phase 3 · registry result, not featured evidence · combination
5.9%
NCT00614939 · Phase 3 · registry result, not featured evidence
—2.5 mg
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
—5 mg
NCT00374907 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT00698932 · Phase 3 · registry result, not featured evidence
1.8%5 mg
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
1%Teneli / Teneli + SUh
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 28 more results
—Teneli/Teneli + SU (Data Through W
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
—Teneli/Teneli + SU (Data Through W
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.6%Teneligliptin
NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
9%Teneligliptin + Sulfonylurea
NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3
0%Teneli (Teneligliptin) /Teneli + I
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
—Teneli (Teneligliptin) /Teneli + I
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
—Teneli (Teneligliptin)/Teneli + In
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
1.6%20 mg
NCT02924064 · Phase 3 · registry result, not featured evidence · combination
0%20 mg
NCT02916706 · Phase 3 · registry result, not featured evidence
4.6%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02354222 · Phase 3 · registry result, not featured evidence · combination
3.3%Teneligliptin
NCT01301833 · Phase 3 · registry result, not featured evidence
6.7%Teneligliptin and Alpha-glucosidas
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
5.3%Teneligliptin and Biguanide
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
6.3%Teneligliptin and Glinide
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
—20 mg
NCT01072331 · Phase 3 · registry result, not featured evidence
—10 mg
NCT01072331 · Phase 3 · registry result, not featured evidence
2%20 mg
NCT00998881 · Phase 3 · registry result, not featured evidence
—40 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
2.3%40 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—20 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
2.2%20 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—10 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
3.2%10 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
2.3%5 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
1.3%20 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
2.5%40 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
Serious AEs
12.2%10 mgg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 43 more results
14.1%5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
12%2.5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.2%10 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
17%5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
10.8%2.5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.8%
NCT02024477 · Phase 4 · registry result, not featured evidence
12.5%10mg
NCT02471404 · Phase 4 · registry result, not featured evidence
7.1%5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
2.1%
NCT02243176 · Phase 4 · registry result, not featured evidence
1.8%
NCT01608724 · Phase 4 · registry result, not featured evidence
25.5%
NCT01107886 · Phase 4 · registry result, not featured evidence
11.4%5 mg
NCT01006603 · Phase 4 · registry result, not featured evidence
4.1%
NCT01006590 · Phase 4 · registry result, not featured evidence · add on
0%5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
3.8%5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence · combination
2.3%2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
1.6%2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
4.9%2.5 mg
NCT03199053 · Phase 3 · registry result, not featured evidence
—Saxagliptin
NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy
12.8%dapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
6.2%
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
2.4%
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
3.9%
NCT02284893 · Phase 3 · registry result, not featured evidence · combination
0%
NCT01204775 · Phase 3 · registry result, not featured evidence
0%
NCT01434186 · Phase 3 · registry result, not featured evidence
5.1%5 mg QD
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
—Saxagliptin Plus Insulin
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
4.4%DAPA + SAXA + MET
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
—Dapa+Saxa+Met
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
4.6%5 mg
NCT01619059 · Phase 3 · registry result, not featured evidence · combination
1.1%
NCT01606007 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT01128153 · Phase 3 · registry result, not featured evidence
0%
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
12.6%
NCT00575588 · Phase 3 · registry result, not featured evidence · combination
0%5 mg
NCT00918879 · Phase 3 · registry result, not featured evidence
2.2%5 mg + Metformin XR 1500 mg
NCT00918138 · Phase 3 · registry result, not featured evidence · combination
8.2%5 mg
NCT00757588 · Phase 3 · registry result, not featured evidence · combination
27.1%
NCT00614939 · Phase 3 · registry result, not featured evidence
1.4%2.5 mg
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
5%5 mg
NCT00374907 · Phase 3 · registry result, not featured evidence
2.8%5 mg
NCT00698932 · Phase 3 · registry result, not featured evidence
2.8%5 mg
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
—Teneli / Teneli + SUh
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 28 more results
0%Teneli/Teneli + SU (Data Through W
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.3%Teneli/Teneli + SU (Data Through W
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
4%Teneligliptin
NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
7.9%Teneligliptin + Sulfonylurea
NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3
—Teneli (Teneligliptin) /Teneli + I
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
6.5%Teneli (Teneligliptin) /Teneli + I
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
1.3%Teneli (Teneligliptin)/Teneli + In
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
3.2%20 mg
NCT02924064 · Phase 3 · registry result, not featured evidence · combination
4.7%20 mg
NCT02916706 · Phase 3 · registry result, not featured evidence
7.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
1.3%
NCT02354222 · Phase 3 · registry result, not featured evidence · combination
6.6%Teneligliptin
NCT01301833 · Phase 3 · registry result, not featured evidence
8%Teneligliptin and Alpha-glucosidas
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
6.3%Teneligliptin and Biguanide
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
3.8%Teneligliptin and Glinide
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
0%20 mg
NCT01072331 · Phase 3 · registry result, not featured evidence
0%10 mg
NCT01072331 · Phase 3 · registry result, not featured evidence
0%20 mg
NCT00998881 · Phase 3 · registry result, not featured evidence
5.7%40 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—40 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
3.3%20 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—20 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
4.3%10 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
—10 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
4.6%5 mg
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
0%20 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
10 mgg
influenza 15.5% (placebo 15.1%)
nasopharyngitis 15.5% (placebo 14%)
headache 13.3% (placebo 12.3%)
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 37 more results
5 mg
influenza 16.2% (placebo 15.1%)
nasopharyngitis 14.7% (placebo 14%)
arthralgia 10.5% (placebo 6.7%)
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.5 mg
diarrhoea 15.1% (placebo 12.8%)
nasopharyngitis 14.6% (placebo 14%)
headache 14.1% (placebo 12.3%)
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
10 mg
arthralgia 16.3% (placebo 7.4%)
headache 16.3% (placebo 16.8%)
influenza 15.3% (placebo 6.3%)
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
upper respiratory tract infection 15.1% (placebo 15.8%)
urinary tract infection 13.2% (placebo 8.4%)
headache 12.3% (placebo 16.8%)
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.5 mg
diarrhoea 13.7% (placebo 8.4%)
upper respiratory tract infection 11.8% (placebo 15.8%)
influenza 10.8% (placebo 6.3%)
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
10mg
nasopharyngitis 9.3%
NCT02471404 · Phase 4 · registry result, not featured evidence
5mg and 10mg
nasopharyngitis 9.9%
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
hyperlipidaemia 6.2%
hyperlipidaemia 3.7%
abdominal distension 1.2%
NCT02243176 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 2.7%
dizziness 2.6%
NCT01608724 · Phase 4 · registry result, not featured evidence
diabetes mellitus 6.5% (placebo 8.1%)
dizziness 4.5% (placebo 4.2%)
hypertension 4.2% (placebo 3.9%)
NCT01107886 · Phase 4 · registry result, not featured evidence
5 mg
nasopharyngitis 6.4%
arthralgia 4.7%
diarrhoea 4.2%
NCT01006603 · Phase 4 · registry result, not featured evidence
hypoglycaemia 6.8%
diarrhoea 6.1%
nasopharyngitis 5.4%
NCT01006590 · Phase 4 · registry result, not featured evidence · add on
5 mg
toothache 7.7% (placebo 0%)
acne 3.8% (placebo 0%)
animal bite 3.8% (placebo 0%)
NCT03199053 · Phase 3 · registry result, not featured evidence
5 mg
aphthous ulcer 3.8% (placebo 0%)
back pain 3.8% (placebo 2.6%)
colitis 3.8% (placebo 0%)
NCT03199053 · Phase 3 · registry result, not featured evidence
5 mg
nasopharyngitis 15.4% (placebo 2.6%)
asthma 7.7% (placebo 0%)
covid-19 7.7% (placebo 2.6%)
NCT03199053 · Phase 3 · registry result, not featured evidence · combination
2.5 mg
vitamin d deficiency 4.5% (placebo 6.6%)
nausea 3.4% (placebo 0%)
urinary tract infection 3.4% (placebo 5.3%)
NCT03199053 · Phase 3 · registry result, not featured evidence
2.5 mg
influenza 4.9% (placebo 2.6%)
bronchitis 1.6% (placebo 0%)
chronic sinusitis 1.6% (placebo 0%)
NCT03199053 · Phase 3 · registry result, not featured evidence
2.5 mg
covid-19 6.6% (placebo 2.6%)
upper respiratory tract infection 6.6% (placebo 2.6%)
urinary tract infection 4.9% (placebo 5.3%)
NCT03199053 · Phase 3 · registry result, not featured evidence
dapagliflozin 10 mg, saxagliptin 5 mg
urinary tract infection 13.7%
upper respiratory tract infection 10.1%
headache 7.9%
NCT02419612 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 7.7%
upper respiratory tract infection 5.2%
headache 3.7%
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
glomerular filtration rate decreased 4.1%
pollakiuria 2.4%
urinary tract infection 2.4%
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
nasopharyngitis 7.8%
headache 5.6%
urinary tract infection 4.3%
NCT02284893 · Phase 3 · registry result, not featured evidence · combination
oropharyngeal pain 50% (placebo 25%)
acne 25% (placebo 0%)
cough 25% (placebo 25%)
NCT01204775 · Phase 3 · registry result, not featured evidence
headache 50% (placebo 0%)
abdominal pain upper 25% (placebo 0%)
back pain 25% (placebo 0%)
NCT01434186 · Phase 3 · registry result, not featured evidence
5 mg QD
hypoglycaemia 21.8% (placebo 23.8%)
upper respiratory tract infection 2.6% (placebo 4.3%)
urinary tract infection 2.6% (placebo 0.9%)
NCT02104804 · Phase 3 · registry result, not featured evidence · combination
urinary tract infection 9.4% (placebo 10%)
influenza 7.5% (placebo 7.5%)
headache 6.9% (placebo 8.1%)
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
5 mg
urinary tract infection 7.2% (placebo 6.8%)
headache 5.9% (placebo 7.4%)
nasopharyngitis 5.9% (placebo 4.9%)
NCT01619059 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 6.2% (placebo 9.4%)
diarrhoea 5.4% (placebo 3.9%)
hypertension 5.4% (placebo 1.6%)
NCT01128153 · Phase 3 · registry result, not featured evidence
diarrhoea 5.8%
urinary tract infection 5.1%
nasopharyngitis 4.3%
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 10.7%
diarrhoea 5.8%
upper respiratory tract infection 5.8%
NCT00575588 · Phase 3 · registry result, not featured evidence · combination
5 mg
urinary tract infection 8.4% (placebo 9.4%)
NCT00918879 · Phase 3 · registry result, not featured evidence
5 mg + Metformin XR 1500 mg
cough 6.5%
NCT00918138 · Phase 3 · registry result, not featured evidence · combination
5 mg
urinary tract infection 7.6% (placebo 7.9%)
nasopharyngitis 6.3% (placebo 6.6%)
upper respiratory tract infection 6.3% (placebo 7.3%)
NCT00757588 · Phase 3 · registry result, not featured evidence · combination
hypoglycaemia 28.2% (placebo 29.4%)
anaemia 5.9% (placebo 8.2%)
hypertension 5.9% (placebo 5.9%)
NCT00614939 · Phase 3 · registry result, not featured evidence
5 mg
headache 25% (placebo 18.8%)
muscle spasms 25% (placebo 0%)
infusion site pain 20% (placebo 12.5%)
NCT00374907 · Phase 3 · registry result, not featured evidence
5 mg
upper respiratory tract infection 6.3% (placebo 7.7%)
NCT00698932 · Phase 3 · registry result, not featured evidence
5 mg
upper respiratory tract infection 6.7% (placebo 4.5%)
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
h
nasopharyngitis 19.8% (placebo 27.4%)
upper respiratory tract inflammation 5.2% (placebo 7.4%)
alanine aminotransferase increased 4.2% (placebo 3.2%)
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 23 more results
nasopharyngitis 33.3% (placebo 27.4%)
protein urine present 16.7% (placebo 13.7%)
glucose urine present 11.5% (placebo 17.9%)
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
nasopharyngitis 37.1%
blood creatine phosphokinase increased 9.3%
protein urine present 9.3%
NCT02314637 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
nasopharyngitis 32.6%
glucose urine present 18%
protein urine present 14.6%
NCT02314637 · Phase 3 · combination · Type 2 Diabetes · phase 3
nasopharyngitis 28.6% (placebo 18.3%)
hypoglycaemia 27.3% (placebo 7%)
constipation 10.4% (placebo 2.8%)
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
hypoglycaemia 11.7% (placebo 7%)
nasopharyngitis 7.8% (placebo 18.3%)
constipation 3.9% (placebo 2.8%)
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
20 mg
upper respiratory tract infection 11.3% (placebo 17.9%)
hyperuricaemia 8.9% (placebo 10.6%)
hyperlipidaemia 6.5% (placebo 5.7%)
NCT02924064 · Phase 3 · registry result, not featured evidence · combination
20 mg
upper respiratory tract infection 23.6% (placebo 15.7%)
hyperuricaemia 8.7% (placebo 4.7%)
proteinuria 7.1% (placebo 3.9%)
NCT02916706 · Phase 3 · registry result, not featured evidence
nasopharyngitis 30.7%
pollakiuria 6.5%
constipation 5.2%
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 15.6% (placebo 10.4%)
upper respiratory tract infection 5.2% (placebo 0%)
NCT02354222 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 29.2%
upper respiratory tract inflammation 9.4%
blood urine present 7.1%
NCT01301833 · Phase 3 · registry result, not featured evidence
nasopharyngitis 28%
upper respiratory tract inflammation 10.7%
eczema 9.3%
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 29.5%
upper respiratory tract inflammation 10.5%
blood urine present 9.5%
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 23.8%
upper respiratory tract inflammation 13.8%
bronchitis 8.8%
NCT01301833 · Phase 3 · registry result, not featured evidence · combination
20 mg
nasopharyngitis 6.1% (placebo 0%)
blood triglycerides increased 3% (placebo 3.1%)
diarrhoea 3% (placebo 0%)
NCT01072331 · Phase 3 · registry result, not featured evidence
10 mg
upper respiratory tract inflammation 8.8% (placebo 0%)
nasopharyngitis 5.9% (placebo 0%)
alanine aminotransferase increased 2.9% (placebo 0%)
NCT01072331 · Phase 3 · registry result, not featured evidence
20 mg
nasopharyngitis 12.1% (placebo 6.7%)
glucose urine present 4% (placebo 6.7%)
upper respiratory tract inflammation 4% (placebo 3.8%)
NCT00998881 · Phase 3 · registry result, not featured evidence
40 mg
nasopharyngitis 8% (placebo 6.8%)
cystitis 5.7% (placebo 1.1%)
gastroenteritis 3.4% (placebo 2.3%)
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
20 mg
diarrhoea 5.5% (placebo 3.4%)
headache 5.5% (placebo 1.1%)
hypertension 3.3% (placebo 2.3%)
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
10 mg
cystitis 4.3% (placebo 1.1%)
nasopharyngitis 4.3% (placebo 6.8%)
bronchitis 3.2% (placebo 1.1%)
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
5 mg
nasopharyngitis 6.9% (placebo 6.8%)
hypertension 5.7% (placebo 2.3%)
bronchitis 3.4% (placebo 1.1%)
NCT00971243 · Phase 2 · registry result, not featured evidence · combination
20 mg
nasopharyngitis 11.4% (placebo 13.8%)
glucose urine present 5.1% (placebo 7.5%)
urine ketone body present 5.1% (placebo 1.3%)
NCT00628212 · Phase 2 · registry result, not featured evidence
10 mg
nasopharyngitis 19% (placebo 13.8%)
blood creatine phosphokinase increased 4.8% (placebo 1.3%)
blood urine present 4.8% (placebo 1.3%)
NCT00628212 · Phase 2 · registry result, not featured evidence
40 mg
nasopharyngitis 17.3% (placebo 13.8%)
arthropod sting 3.7% (placebo 0%)
glucose urine present 3.7% (placebo 7.5%)
NCT00628212 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 4 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cAssessment timepoints differ: 24 weeks versus 52 weeks.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eTreatment context has not been resolved for both arms.
  6. fAssessment timepoints differ: 24 weeks versus 12 weeks.
  7. gPopulation comparability has not been reviewed for 38 of these studies.
  8. hPopulation comparability has not been reviewed for 24 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Saxagliptin

HbA1c -0.58% (n=180) vs 0.13% (n=175) placebo @ 24wk10 mg
absolute change · percentage points
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 8 more results
-0.54% (n=98) vs 0.19% (n=95) placebo @ 24wk10 mg
Adjusted Mean Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.69% (n=186) vs 0.13% (n=175) placebo @ 24wk5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.46% (n=106) vs 0.19% (n=95) placebo @ 24wk5 mg
Adjusted Mean Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.84% (n=277) vs -0.34% (n=274) placebo @ 24wk5 mg
Adjusted Mean Change from Baseline
NCT00698932 · Phase 3 · registry result, not featured evidence
-0.59% (n=186) vs 0.13% (n=175) placebo @ 24wk2.5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.43% (n=102) vs 0.19% (n=95) placebo @ 24wk2.5 mg
Adjusted Mean Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.56% (n=74) vs -0.22% (n=84) placebo @ 12wk2.5 mg
Adjusted Mean Change From Baseline
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
-0.86% (n=81) vs -0.44% (n=83) placebo @ 12wk
Adjusted Mean Change from Baseline
NCT00614939 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose -1.14 vs 0.07 placebo mmol/L @ 24wk10 mg
absolute change · mmol/L
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -20.5 mg/dL as posted
show 6 more results
-1.22 vs 0.07 placebo mmol/L @ 24wk*5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -22.03 mg/dL as posted
-0.9 vs -0.17 placebo mmol/L @ 24wk5 mg
Adjusted mean change from Baseline
NCT00698932 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.17 placebo mmol/L @ 24wk*5 mg
Adjusted mean change from Baseline
NCT00698932 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -16.13 mg/dL as posted
-0.79 vs 0.07 placebo mmol/L @ 24wk*2.5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -14.31 mg/dL as posted
-0.52 vs -0.2 Metformin mmol/L @ 4wk*5 mg + Metformin XR 1500 mg
Adjusted mean change from baseline
NCT00918138 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -9.3 mg/dL as posted
-0.76 vs -0.23 placebo mmol/L @ 12wk*2.5 mg
Adjusted Mean Change from Baseline
NCT00885378 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -13.73 mg/dL as posted
HbA1c Less Than 7% 44.4% (n=180) vs 16.6% (n=175) placebo @ 24wk10 mg
responder rate · % of participants
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 15 more results
41.1% (n=95) vs 23.9% (n=92) placebo @ 24wk10 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
44.3% (n=227) vs 34.3% (n=216) Glimepiride @ 52wkdapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
21.4% (n=227) vs 11.7% (n=216) Glimepiride @ 156wkdapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
43.5% (n=186) vs 16.6% (n=175) placebo @ 24wk5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
37.9% (n=103) vs 23.9% (n=92) placebo @ 24wk5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
22.1% (n=104) vs 13.3% (n=105) placebo @ 24wk5 mg
NCT00918879 · Phase 3 · registry result, not featured evidence
45.8% (n=277) vs 28.8% (n=274) placebo @ 24wk5 mg
NCT00698932 · Phase 3 · registry result, not featured evidence
37.1% (n=186) vs 16.6% (n=175) placebo @ 24wk2.5 mg
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
35% (n=100) vs 23.9% (n=92) placebo @ 24wk2.5 mg
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
37.5% (n=73) vs 24.2% (n=84) placebo @ 12wk2.5 mg
NCT00885378 · Phase 3 · registry result, not featured evidence · combination
38.3% (n=230) vs 41.5% (n=229) Acarbose @ 24wk
NCT02243176 · Phase 4 · registry result, not featured evidence
21.3% (n=61) vs 10% (n=50) placebo @ 26wk
NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy
37.3% (n=224) vs 25.1% (n=219) Sita + Met @ 26wk
NCT02284893 · Phase 3 · registry result, not featured evidence · background therapy
36.7% (n=158) vs 13.3% (n=158) placebo @ 24wk
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
37.2% (n=137) vs 26.1% (n=142) Metformin (DB) + Metformin (OL) @ 18wk
NCT00960076 · Phase 3 · registry result, not featured evidence · combination
Postprandial Glucose AUC -8137 vs -3291 placebo mg @ 24wk10 mg
absolute change · mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-9586 vs -3291 placebo mg @ 24wk5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
-7534 vs -4255 placebo mg @ 24wk5 mg
Adjusted mean change from Baseline
NCT00698932 · Phase 3 · registry result, not featured evidence
-8891 vs -3291 placebo mg @ 24wk2.5 mg
Adjusted Mean Change from Baseline
NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3
Fasting Plasma Glucose -0.93 vs 0.34 placebo mmol/L @ 24wk10 mg
absolute change · mmol/L
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -16.75 mg/dL as posted
show 4 more results
-0.48 vs 0.34 placebo mmol/L @ 24wk*5 mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -8.67 mg/dL as posted
-1.14 vs -0.58 placebo mmol/L @ 24wk5 mg
Adjusted Change from Baseline
NCT00661362 · Phase 3 · registry result, not featured evidence · combination
-1.14 vs -0.58 placebo mmol/L @ 24wk*5 mg
Adjusted Change from Baseline
NCT00661362 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -20.52 mg/dL as posted
-0.81 vs 0.34 placebo mmol/L @ 24wk*2.5 mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -14.53 mg/dL as posted
Postprandial Glucose AUC -8084 vs -646.6 placebo mg @ 24wk10 mg
absolute change · mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 2 more results
-6896 vs -646.6 placebo mg @ 24wk5 mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
-6868 vs -646.6 placebo mg @ 24wk2.5 mg
Adjusted Change from Baseline
NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c 6.8% (n=21) vs 6.6% (n=21) placebo @ 6wk
absolute value · percentage points
Visit 2 - Week 6
NCT02024477 · Phase 4 · registry result, not featured evidence
HbA1c 6.7% (n=21) vs 6.5% (n=21) placebo @ 12wk
absolute value · percentage points
Visit 3 - Week 12
NCT02024477 · Phase 4 · registry result, not featured evidence
Weight -3.54 vs 1.76 Glimepiride kg @ 52wk10mg
absolute change · kg
NCT02471404 · Phase 4 · registry result, not featured evidence
show 7 more results
-3.11 vs 0.95 Glimepiride kg @ 52wkdapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
-3.15 vs 1.76 Glimepiride kg @ 52wk5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
-1.36 vs -2.05 Acarbose kg @ 24wk
NCT02243176 · Phase 4 · registry result, not featured evidence
-1.5 vs 2.14 Titrated Insulin kg @ 24wk
NCT02551874 · Phase 3 · registry result, not featured evidence · combination
-2.01 vs -0.41 Saxagliptin + Metformin kg @ 24wk
NCT02681094 · Phase 3 · registry result, not featured evidence · add on
-1.86 vs -0.51 Sita + Met kg @ 26wk
NCT02284893 · Phase 3 · registry result, not featured evidence · background therapy
-1.91 vs -0.41 placebo kg @ 24wk
NCT01646320 · Phase 3 · registry result, not featured evidence · combination
Time to Rescue Medication NA vs NA Glimepiride months @ 52wk10mg
time to event · months
NCT02471404 · Phase 4 · registry result, not featured evidence
show 2 more results
NA vs 21.3 Glimepiride months @ 156wkdapagliflozin 10 mg, saxagliptin 5 mg
NCT02419612 · Phase 3 · registry result, not featured evidence
NA vs NA Glimepiride months @ 52wk5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
Rescue 18.6% (n=311) vs 21.4% (n=309) Glimepiride @ 52wk10mg
responder rate · % of participants
NCT02471404 · Phase 4 · registry result, not featured evidence
show 1 more result
8.3% (n=312) vs 21.4% (n=309) Glimepiride @ 52wk5mg and 10mg
NCT02471404 · Phase 4 · registry result, not featured evidence · combination
HbA1c Less Than 7 Without GI AE 37% (n=230) vs 28.8% (n=229) Acarbose @ 24wk
responder rate · % of participants
NCT02243176 · Phase 4 · registry result, not featured evidence

+ 43 further endpoints in the CSV export.

Teneligliptin

AUC0-2h PPG -73.124 vs 0.224 placebo mg @ 12wk20 mg
absolute change · mg
NCT00998881 · Phase 3 · registry result, not featured evidence
show 5 more results
-73.211 vs 5.897 placebo mg @ 12wk20 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
-65.445 vs 5.897 placebo mg @ 12wk10 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
-75.326 vs 5.897 placebo mg @ 12wk40 mg
NCT00628212 · Phase 2 · registry result, not featured evidence
-65.544 vs 15.514 placebo mg @ 12wk
NCT00974090 · Phase 3 · combination · Type 2 Diabetes · phase 3
-54.035 vs 9.827 placebo mg @ 16wk
NCT02081599 · Phase 4 · registry result, not featured evidence · combination
Weight -3.92% (n=152) @ 52wk
percent change · % of baseline
No placebo or comparator arm
NCT02220907 · Phase 3 · registry result, not featured evidence · combination
Weight 0.09% (n=77) vs -1.34% (n=76) placebo @ 24wk
percent change · % of baseline
NCT02354222 · Phase 3 · registry result, not featured evidence · combination
AUC0-2h PPG -2.79 vs 0.32 placebo mmol/L @ 24wk
absolute change · mmol/L
NCT02354222 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -50.2 mg/dL as posted
Glucose Change mg/dL -1.72 vs -0.3 placebo mmol/L @ 4wk20 mg
absolute change · mmol/L
NCT01072331 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -30.921 mg/dL as posted
show 1 more result
-1.93 vs -0.3 placebo mmol/L @ 4wk*10 mg
NCT01072331 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -34.722 mg/dL as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Saxagliptin's landscape · Teneligliptin's landscape